Advertisement

Be aware of the risk of drug-induced kidney stones and take appropriate steps to prevent or treat their occurrence

  • Adis Medical Writers
Drug Reactions and Interactions
  • 2 Downloads

Abstract

Drug-induced kidney stones can form when poorly soluble drugs with high levels of renal excretion (e.g. protease inhibitors and sulfonamides) crystallise in the urine, as well as when drugs with metabolic effects (e.g. calcium + vitamin D supplements and carbonic anhydrase inhibitors) promote the crystallisation of metabolic compounds. Methods such as infrared spectroscopy and X-ray diffraction should be used to determine whether a drug or its metabolites are present in stones or crystals, while a careful clinical inquiry is necessary to successfully distinguish between common calculi and metabolically-induced stones. Kidney stones can often be prevented or treated through the modification of risk factors, such as urine output.

Notes

Compliance with ethical standards

Conflict of interest

The article was adapted from Drugs 2018;78(2)163-201 [1] by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.

Funding

The preparation of this review was not supported by any external funding.

References

  1. 1.
    Daudon M, Frochot V, Bazin D, et al. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163–201.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Couzigou C, Daudon M, Meynard JL, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007;45(8):e105–8.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Rockwood N, Mandalia S, Bower M, et al. Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. AIDS. 2011;25(13):1671–3.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    de Lastours V, De Silva EFR, Daudon M, et al. High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother. 2013;68(8):1850–6.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs. 2004;64(3):245–75.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Daudon M, Estépa L, Viard JP, et al. Indinavir crystalluria in HIV-positive patients treated with indinavir sulfate. In: Rodgers AL, Hibbert BE, Hess B, Khan SR, Preminger GM, editors. Urolithiasis 2000. Cape Town: University of Cape Town; 2000. p. 335–7.Google Scholar
  7. 7.
    Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS. 1998;12(18):F249–54.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol. 2000;54(4):261–70.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Daudon M, Estépa L, Viard JP. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet. 1997;349(9061):1294–5.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Izzedine H, Lescure FX, Bonnet F. HIV medication-based urolithiasis. Clin Kidney. 2014;7(2):121–6.CrossRefGoogle Scholar
  11. 11.
    Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol. 2002;167(3):1384–5.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Raymond JR. Amphotericin B nephrotoxicity. Am Fam Physician. 1988;38(2):199–203.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Asper R. Iatrogenic urinary calculi: detection and identification by X-ray diffraction. Clin Chem. 1986;24(10):767–8.Google Scholar
  14. 14.
    Youssef DM, Sherief LM, Sherbiny HS, et al. Prospective study of nephrolithiasis occurrence in children receiving ceftriaxone. Nephrology. 2015;21(5):432–7.CrossRefGoogle Scholar
  15. 15.
    Zhang Y, Ning B, Zhu H, et al. Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review. Int Urol Nephrol. 2016;48(7):1061–9.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Thorsteinsson SB, Bergan T, Rohwedder R. Tolerance of intravenously administered ciprofloxacin. Chemotherapy. 1988;34(3):256–60.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Thorsteinsson SB, Bergan T, Oddsdottir S, et al. Crystalluria and ciprofloxacin, influence of urinary pH and hydration. Chemotherapy. 1986;32(5):408–17.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Bennett S, Hoffman N, Monga M. Ephedrine- and guaifenesin-induced nephrolithiasis. J Altern Complement Med. 2005;10(6):967–9.CrossRefGoogle Scholar
  19. 19.
    Powell T, Hsu FF, Turk J, et al. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32(1):153–9.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Gabardi S, Carter D, Martin S, et al. Recommendations for the proper use of nonprescription cough suppressants and expectorants in solid-organ transplant recipients. Prog Transplant. 2011;21(1):6–13.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Perazella MA. Crystal-induced acute renal failure. Am J Med. 1999;106(4):459–65.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Carey RA, Beg MM, McNally CF, et al. Triamterene and renal lithiasis: a review. Clin Ther. 1984;6(3):302–9.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Ettinger B, Oldroyd NO, Sörgel F. Triamterene nephrolithiasis. JAMA. 1980;244:2443–5.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Jick H, Dinan BJ, Hunter JR. Triamterene and renal stones. J Urol. 1982;127(2):224–5.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylindruria: clinical and experimental studies. Clin Nephrol. 1986;26(4):169–73.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Lynn KL, Bailey RR, Swainson CP, et al. Renal failure with potassium-sparing diuretics. NZ Med J. 1985;98(784):629–33.Google Scholar
  27. 27.
    Nguyen Quy D, Daudon M. Infrared and Raman spectra of calculi. Paris: Elsevier; 1997.Google Scholar
  28. 28.
    Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5(10):563–73.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–83.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Lappe J, Watson P, Travers-Gustafson D, et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women. JAMA. 2017;317(12):1234–43.CrossRefPubMedCentralGoogle Scholar
  31. 31.
    Ferraro PM, Taylor EN, Gambaro G, et al. Vitamin D intake and the risk of incident kidney stones. J Urol. 2017;197:405–10.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Johri N, Jaeger P, Ferraro PM, et al. Vitamin D deficiency is prevalent among idiopathic stone formers, but does correction pose any risk? Urolithiasis. 2017;45:535–43.CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Seidowsky A, Villain C, Vilaine E, et al. Hypercalcemia and inactive mutation of CYP24A1: case-study and literature review. Nephrol Ther. 2017;13(3):146–53.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Daudon M, Lacour B, Jungers P, et al. Urolithiasis in patients with end stage renal failure. J Urol. 1992;147(4):977–80.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology. 1990;40(11):1677–81.CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Daudon M. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol. 2004;98(2):31–6.CrossRefGoogle Scholar
  37. 37.
    Ahlstrand C, Tiselius H-G. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol. 2010;21(3):225–8.CrossRefGoogle Scholar
  38. 38.
    Maalouf NM. Nephrolithiasis in topiramate users. Urol Res. 2011;39(4):303–7.CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765–73.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Hufnagle KG, Khan SN, Penn D, et al. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics. 1982;70(3):360–3.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kim Y-G, Kim B, Kim M-K, et al. Medullary nephrocalcinosis associated with long-term furosemide abuse in adults. Nephrol Dial Transplant. 2001;16(12):2303–9.CrossRefPubMedCentralGoogle Scholar
  42. 42.
    Böhles H, Gebhardt B, Beeg T, et al. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr. 2002;140(1):103–9.CrossRefPubMedCentralGoogle Scholar
  43. 43.
    Terribile M, Capuano M, Cangiano G, et al. Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol Dial Transplant. 2006;21(7):1870–5.CrossRefPubMedCentralGoogle Scholar
  44. 44.
    Ferraro PM, Curhan GC, Gambaro G, et al. Total, dietary, and supplemental vitamin C intake and risk of incident kidney stones. Am J Kidney Dis. 2016;67(3):400–7.CrossRefPubMedCentralGoogle Scholar
  45. 45.
    Schaefer M, Littrell E, Khan A, et al. Estimated GFR decline following sodium phosphate enemas versus polyethylene glycol for screening colonoscopy: a retrospective cohort study. Am J Kidney Dis. 2016;67(4):609–16.CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Rapado A, Traba ML, Caycho C, et al. Drug-induced renal stones: incidence, clinical expression and stone analysis. Contrib Nephrol. 1987;58:25–9.CrossRefPubMedCentralGoogle Scholar
  47. 47.
    Daudon M, Estepa L. Drug induced lithiases [in French]. Presse Med. 1998;27(14):675–83.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Cohen-Solal F, Abdelmoula J, Hoarau MP, et al. Urinary lithiasis of medical origin [in French]. Therapie. 2001;56(6):743–50.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Daudon M, Protat MF, Reveillaud RJ. Detection and diagnosis of drug-induced urinary calculi [in French]. Ann Biol Clin. 1983;41(4):239–49.Google Scholar
  50. 50.
    Daudon M, Réveillaud RJ. Drug nephrolithiasis: an unrecognized and underestimated pathology. In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W, editors. Urolithiasis and related clinical research. New York: Plenum; 1985. p. 371–4.CrossRefGoogle Scholar
  51. 51.
    Matlaga BR, Shah OD, Assimos DG. Drug-induced urinary calculi. Rev Urol. 2003;5(4):227–31.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Daudon M. Drug-induced urinary calculi in 1999 [in French]. Prog Urol. 1999;9(6):1023–33.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations